studies

lung cancer : non small cell (NSCLC), ... vs. docetaxel, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsDELTA, 2014 0.91 [0.68; 1.22] 0.91[0.68; 1.22]DELTA, 201410%301NAnot evaluable progression or deaths (PFS)detailed resultsDELTA, 2014 1.22 [0.97; 1.54] 1.22[0.97; 1.54]DELTA, 201410%301NAnot evaluable objective responses (ORR)detailed resultsDELTA, 2014 0.96 [0.53; 1.76] 0.96[0.53; 1.76]DELTA, 201410%301NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-07-01 18:04 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334 - treatments: 430